TABLE 2.
Clinical presentation and management of MAB patients
| All MAB d patients (N = 93) | No hospitalization for COVID‐19 a (N = 85) | Hospitalization for COVID‐19 a (N = 8) | p‐value | |
|---|---|---|---|---|
| Symptoms prior to infusion * | ||||
| Fever | 41 (44.1) | 36 (42.3) | 5 (62.5) | 0.273 |
| Cough | 76 (81.7) | 68 (80.0) | 8 (100.0) | 0.162 |
| Shortness of breath | 47 (50.5) | 40 (47.1) | 7 (87.5) | 0.029 |
| Diarrhea | 43 (46.2) | 39 (45.9) | 4 (50.0) | 0.823 |
| Congestion | 71 (76.3) | 65 (76.5) | 6 (75.0) | 0.925 |
| Sore throat | 29 (31.2) | 26 (30.6) | 3 (37.5) | 0.687 |
| Loss of taste | 9 (9.7) | 9 (10.6) | 0 (0) | 0.333 |
| Loss of smell | 24 (25.8) | 24 (28.2) | 0 (0) | 0.081 |
| Fatigue | 71 (76.3) | 64 (75.3) | 7 (87.5) | 0.437 |
| Myalgias | 57 (61.3) | 52 (61.2) | 5 (62.5) | 0.941 |
| Headache | 63 (67.8) | 58 (68.2) | 5 (62.5) | 0.740 |
| Nausea | 35 (37.6) | 31 (36.5) | 4 (50.0) | 0.450 |
| Vomiting | 12 (12.9) | 11 (12.9) | 1 (12.5) | 0.972 |
| Monoclonal antibody | ||||
| Bamlanivimab | 71 (76.3) | 63 (74.1) | 8 (100.0) | 0.100 |
| Casirivimab‐Imdevimab | 22 (23.7) | 22 (25.9) | 0 (0) | |
| Time from COVID‐19 a diagnosis to MAB d therapy, days | 3 (2–5) | 3 (2–5) | 4 (2.5–5) | 0.588 |
Note: Values are expressed as frequencies (percentages).
*
Not mutually exclusive.
**
Therapy started after presenting to emergency department or hospital.
a
Coronavirus disease 2019.
bImmunosuppression.
cMycophenolate mofetil.
d
Monoclonal antibody.
eEmergency department.